β受体阻滞剂对疑似脓毒症患者乳酸水平的影响——BeLLa研究
该前瞻性观察研究在新加坡一家三级学术医疗中心急诊科纳入195例年龄≥45岁、鼓膜温度≥37.8 °C或临床疑似感染、且qSOFA评分≥1的疑似脓毒症患者,在就诊2小时内采样血清静脉乳酸。主要结局为长期使用β受体阻滞剂者与未使用者初始血清静脉乳酸浓度的差异。结果显示,70例(35.9%)长期使用β受体阻滞剂,两组平均初始血清静脉乳酸浓度相似(1.78 mmol/L vs 1.70 mmol/L,p=0.540),且在各脓毒症风险分层亚组中长期β受体阻滞剂治疗也均未显著影响平均初始血清静脉乳酸浓度。结论认为,长期β受体阻滞剂治疗未显著影响急诊疑似脓毒症患者的初始血清静脉乳酸浓度。
要点
- 在急诊疑似脓毒症患者中,长期β受体阻滞剂治疗者与未使用者的平均初始血清静脉乳酸浓度相似(1.78 mmol/L vs 1.70 mmol/L,p=0.540)。
- 长期β受体阻滞剂治疗在各脓毒症风险分层亚组中均未显著影响平均初始血清静脉乳酸浓度。
- 研究纳入年龄≥45岁、鼓膜温度≥37.8 °C或临床疑似感染、且qSOFA评分≥1的急诊患者,血清静脉乳酸在就诊2小时内采样。
- 195例纳入患者中70例(35.9%)长期使用β受体阻滞剂。
适用人群与场景
- 急诊科疑似脓毒症患者,纳入标准为年龄≥45岁、鼓膜温度≥37.8 °C或临床疑似感染、且qSOFA评分≥1。
诊断标准与关键阈值
- qSOFA评分≥1作为纳入标准之一。
- 鼓膜温度≥37.8 °C或临床疑似感染作为纳入标准之一。
研究设计与关键结果
- 研究类型为前瞻性观察研究,在新加坡一家三级学术医疗中心急诊科进行,纳入195例疑似脓毒症患者。
- 70例(35.9%)患者长期使用β受体阻滞剂。
- 主要结局:长期β受体阻滞剂治疗者与未使用者平均初始血清静脉乳酸浓度相似(1.78 mmol/L vs 1.70 mmol/L,p=0.540)。
- 长期β受体阻滞剂治疗在各脓毒症风险分层亚组中均未显著影响平均初始血清静脉乳酸浓度。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急诊疑似脓毒症患者中,长期β受体阻滞剂治疗未显著影响初始血清静脉乳酸浓度,提示初始乳酸水平解读时无需因长期β受体阻滞剂使用而特别调整。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: In the assessment and management of septic patients in the emergency department (ED), serum lactate is often measured to stratify severity to guide decision making. Increased adrenergic drive has been postulated as a contributory factor for hyperlactatemia in sepsis. We aim to prospectively evaluate the effect of chronic beta-blocker use on serum lactate levels in sepsis at initial presentation to the ED.
METHODS: We conducted a prospective observational study at the ED of a tertiary care academic medical center in Singapore. One hundred and ninety-five ED patients who fulfilled all of the following: (1) age 45 years and above, (2) tympanic temperature ≥ 37.8 °C or clinically suspected to have an infection, and (3) quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) score ≥ 1 were included in the study. Serum venous lactate was sampled within two hours from presentation to the ED. The primary outcome measure was the difference in initial serum venous lactate concentration at presentation to the ED in patients on chronic beta-blockers versus patients without.
RESULTS: Seventy patients (35.9%) were on long-term beta-blocker therapy. The primary outcome of mean initial serum venous lactate concentration was similar between patients prescribed chronic beta-blocker therapy and patients without (1.78 mmol/L versus 1.70 mmol/L, p = .540). Chronic beta-blocker therapy also did not significantly affect mean initial serum venous lactate concentration across all subgroups of sepsis risk stratification.
CONCLUSIONS: Long-term beta-blocker therapy did not significantly affect initial serum venous lactate concentration in ED patients with suspected sepsis.
参考来源
- Chan JZW, Tan JH, Lather KS, et al. Beta-blockers' effect on Levels of Lactate in patients with suspected sepsis - The BeLLa study. Am J Emerg Med. 2019. PMID: 31902697. doi:10.1016/j.ajem.2019.12.046
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。